US equities |
MU $1,035.84 ▲+0.00% NVDA $230.48 ▲+0.00% SPCX $160.57 ▲+0.00% SNDK $1,609.46 ▲+0.00% AAPL $340.42 ▲+0.00% INTC $107.08 ▲+0.00% AMD $620.68 ▲+0.00% LITE $1,048.60 ▲+0.00%
FinancialContent

Quanterix Corporation - Common Stock (NQ:QTRX)

3.210 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Quanterix Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
From Quanterix
Via Business Wire
News headline image
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Quanterix
Via Business Wire
News headline image
Quanterix Names Dr. Yuri Fesko Chief Medical Officer
From Quanterix
Via Business Wire
News headline image
Quanterix Names Jim Gute Chief Commercial Officer
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Releases Financial Results for the Second Quarter of 2026
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Quanterix Corporation
Via Business Wire
News headline image
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Quanterix
Via Business Wire
News headline image
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Announces Planned Transition of Chief Financial Officer
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Releases Financial Results for the First Quarter of 2026
From Quanterix Corporation
Via Business Wire
News headline image
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows
From Quanterix
Via Business Wire
News headline image
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
From Quanterix Corporation
Via Business Wire
News headline image
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Debuts Content Innovation Engine at AACR 2026
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Corporation Announces Date of 2026 Annual Meeting
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
From Quanterix Corporation
Via Business Wire
News headline image
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
From Quanterix
Via Business Wire
News headline image
Quanterix to Participate in Upcoming Investor Conferences
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
From Quanterix
Via Business Wire
News headline image
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
From Quanterix Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >